Evidence map›Paper›PMID 38760594›Full record

ArticleVirchows Archiv : an international journal of pathology2025

Beyond histology: A tissue algorithm predictive of post-surgical recurrence in hepatocellular carcinomas, including TERT promoter mutation.

Francesco Vasuri, Stefano Chillotti, Thais Maloberti, Elisa Albertini, Giuliana Germinario, Matteo Cescon, Matteo Ravaioli, Dario de Biase, Antonia D'Errico

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Francesco VasuriPathology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Stefano ChillottiPathology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Thais MalobertiSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Elisa AlbertiniPathology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Giuliana GerminarioHepato-Biliary and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Matteo CesconHepato-Biliary and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Matteo RavaioliHepato-Biliary and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.
Dario de BiaseSolid Tumor Molecular Pathology Laboratory, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy. dario.debiase@unibo.it.ORCID http://orcid.org/0000-0002-0609-8817
Antonia D'ErricoPathology Unit, IRCCS Azienda Ospedaliero-Universitaria Di Bologna, Bologna, Italy.

Funding

Fondazione Cassa di Risparmio in Bologna 2021.0144Ministero della Salute RC-2023-2778858
6 · The paper itself

Abstract

Surgical resection for hepatocellular carcinoma (HCC) is burdened with a high recurrence rate and a lack of reliable prognostic factors. The aim of this study was to integrate the HCC pathological features with gene mutations to improve the prognostic role of pathological analysis. This is a monocentric prospective study, including 67 patients resected for HCC. All clinical data and histological features were collected, including tumor grade, architecture, margins, microvascular invasion, and microscopic portal vascular invasion (MPVI). Next-generation sequencing (NGS) was performed using a laboratory-developed multi-gene panel, allowing to amplify 330 amplicons (21.77 kb), covering the relevant targets for solid tumor analysis. The most represented mutations were TERT promoter (n = 41, 61.2%), TP53 (n = 18, 26.9%) and CTNNB1 (n = 17, 25.4%). At follow-up, 13 (19.4%) patients experienced HCC recurrence: at multivariate analysis, tumor dimensions (p = 0.040), MPVI (p = 0.010), and TERT mutation (p = 0.034) correlated with recurrence. Dimensions ≥ 4.5 cm (very close to AJCC stage pT3; 9 recurrences, p = 0.041, odd-ratio = 3.7), MPVI (9 recurrences, p = 0.062, OR = 3.3), and TERT (11 recurrences, p = 0.049, OR = 4.4) correlated with disease-free survival also at univariate analysis. The concomitant occurrence of these three variables was present in 7 cases, among which 5 recurred (p = 0.002, OR = 15.94). In conclusion, NGS analysis in resected HCC could not only be used for future therapies but should be integrated with histopathology to predict the risk of tumor recurrence after surgical resection: TERT mutation is among the strongest predictors of tumor recurrence, together with tumor stage (dimensions) and the occurrence of MPVI, which should always be reported separately from the classic MVI.

Indexed as

AlgorithmsBiomarkers, TumorCarcinoma, HepatocellularLiver NeoplasmsMutationNeoplasm Recurrence, LocalTelomeraseAdultAgedFemaleHepatectomyHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisBiomarkers, TumorTelomeraseTERT protein, humanHepatocellular carcinomaHistopathologyNext-generation sequencingTERT promoterTumor recurrence

Identifiers

PMID38760594
PMCPMC11876287

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.